Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
12.40
-0.34 (-2.67%)
Aug 8, 2025, 11:39 AM - Market open

Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.

The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Avadel Pharmaceuticals plc
Avadel Pharmaceuticals logo
CountryIreland
Founded2015
IPO DateJun 7, 1996
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees188
CEOGregory Divis

Contact Details

Address:
10 Earlsfort Terrace
Dublin, D02 T380
Ireland
Phone353 1 901 5201
Websiteavadel.com

Stock Details

Ticker SymbolAVDL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001012477
CUSIP Number05337M104
ISIN NumberUS05337M1045
SIC Code2834

Key Executives

NamePosition
Gregory J. Divis Jr.Chief Executive Officer and Director
Thomas S. McHughSenior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer
Jerad G. SeurerGeneral Counsel, Company Secretary and Compliance Officer
Susan RodriguezChief Operating Officer
Gregory J. DavisVice President of Corporate and Business Development
Mark W. ElrodVice President of Sales
Angie WoodsVice President of People and Culture
Dr. Jordan S. Dubow M.D., Ph.D.Consultant
Dr. Jason M. VaughnSenior Vice President of Technical Operations
Jennifer Gudeman PharmDSenior Vice President of Medical and Clinical Affairs

Latest SEC Filings

DateTypeTitle
Aug 7, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 7, 2025S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuers
Aug 7, 202510-QQuarterly Report
Aug 7, 20258-KCurrent Report
Jul 29, 20258-KCurrent Report
Jul 29, 2025SCHEDULE 13GFiling
Jul 29, 2025SCHEDULE 13GFiling
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 14, 2025PX14A6GNotice of exempt solicitation submitted by non-management
Jun 30, 2025PX14A6GNotice of exempt solicitation submitted by non-management